Quality of Life Analyses from the Randomized, Open-Label, Phase III PointBreak Study of Pemetrexed-Carboplatin-Bevacizumab followed by Maintenance Pemetrexed-Bevacizumab Versus Paclitaxel-Carboplatin-Bevacizumab followed by Maintenance Bevacizumab in Patients with Stage IIIB or IV Nonsquamous Non–Small-Cell Lung Cancer

作者：David R. Spigel, Jyoti D. Patel, Craig H. Reynolds, Edward B. Garon, Robert C. Hermann, Ramaswamy Govindan, Mark R. Olsen, Katherine B. Winfree, Jian Chen, Jingyi Liu, Susan C. Guba, Mark A. Socinski, Philip Bonomi · 发表于：Journal of Thoracic Oncology · 年份：2015 · DOI：10.1097/jto.0000000000000277 · 被引用次数：29 · 研究领域：Lung Cancer Treatments and Mutations、Cancer Treatment and Pharmacology、Lung Cancer Research Studies